Amgen (AMGN, Biotechnology) Stock Valuation & Fair Value Trading above its usual valuation
Amgen (AMGN, Biotechnology) trades at a blended P/E of 17.7, about 25% above its historical normal valuation, with a forward growth estimate of 5.6% and a PEG of 3.17. Analysts' one-year estimates have been hit 82% of the time. Priced at its historical normal P/E of 14.2 on the same blended earnings, the 2026-10-02 close of $403.04 corresponds to about $323 a share. This is a valuation reference, not a price target.
- Price $407.44 at the 2026-10-08 close, 1.8% above the 20-day average ($400.31) and 0.8% below the 50-day ($410.58).
- RSI (14) at 50.5.
- 52-week range $282.30 to $444.12: the price is 8.3% below the high and 44.3% above the low.
The Street vs SeerForecast
Wall Street's mean price target for AMGN is $390.94 across 29 analysts, 4.0% below the current price. The average analyst rating is Hold. Our SeerForecast read of the same stock, formed without analyst targets: trading above its usual valuation. When the two disagree, start your digging there.
Valuation flags
- Overvalued by 25%
Verdict history
tickerseer's rating moved from mixed on our tests (2026-06-10) to trading above its usual valuation (2026-10-05).
Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.
Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.
Show all 36 weeks
Frequently asked questions
Is Amgen stock overvalued?
At a blended P/E of 17.7 versus its historical normal P/E of 14.2, Amgen trades about 25% above its typical valuation, with a PEG of 3.17 on 5.6% forward growth. tickerseer currently rates it trading above its usual valuation.
What is Amgen's fair value and PEG?
Amgen trades at a blended P/E of 17.7 against a historical normal P/E of 14.2, a PEG of 3.17, and a forward growth estimate of 5.6%. Priced at its historical normal P/E of 14.2 on the same blended earnings, the 2026-10-02 close of $403.04 corresponds to about $323 a share. This is a valuation reference, not a price target.
Has tickerseer's rating of Amgen changed?
tickerseer's rating moved from mixed on our tests (2026-06-10) to trading above its usual valuation (2026-10-05).
What is the analyst price target for Amgen?
The mean Wall Street price target for Amgen is $390.94 across 29 analysts, 4.0% below the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.
Industry: Biotechnology. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.